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The malignant phenotype in breast cancer is driven
by eIF4A1-mediated changes in the translational
landscape
A Modelska1, E Turro1,2, R Russell1, J Beaton1, T Sbarrato3, K Spriggs4, J Miller1, S Gräf1,2,5, E Provenzano6,7, F Blows8, P Pharoah6,8,
C Caldas1,6 and J Le Quesne*,1,3
Human mRNA DeXD/H-box helicases are ubiquitous molecular motors that are required for the majority of cellular processes that
involve RNA metabolism. One of the most abundant is eIF4A, which is required during the initiation phase of protein synthesis to
unwind regions of highly structured mRNA that would otherwise impede the scanning ribosome. Dysregulation of protein
synthesis is associated with tumorigenesis, but little is known about the detailed relationships between RNA helicase function and
the malignant phenotype in solid malignancies. Therefore, immunohistochemical analysis was performed on over 3000 breast
tumors to investigate the relationship among expression of eIF4A1, the helicase-modulating proteins eIF4B, eIF4E and PDCD4, and
clinical outcome. We found eIF4A1, eIF4B and eIF4E to be independent predictors of poor outcome in ER-negative disease, while in
contrast, the eIF4A1 inhibitor PDCD4 was related to improved outcome in ER-positive breast cancer. Consistent with these data,
modulation of eIF4A1, eIF4B and PCDC4 expression in cultured MCF7 cells all restricted breast cancer cell growth and cycling. The
eIF4A1-dependent translatome of MCF7 cells was defined by polysome profiling, and was shown to be highly enriched for several
classes of oncogenic genes, including G-protein constituents, cyclins and protein kinases, and for mRNAs with G/C-rich 5′UTRs
with potential to form G-quadruplexes and with 3′UTRs containing microRNA target sites. Overall, our data show that
dysregulation of mRNA unwinding contributes to the malignant phenotype in breast cancer via preferential translation of a class of
genes involved in pro-oncogenic signaling at numerous levels. Furthermore, immunohistochemical tests are promising
biomarkers for tumors sensitive to anti-helicase therapies.
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The malignant phenotype is the consequence of dysregulated
gene expression. Most regulation occurs post-transcriptionally,1
and the major determinant of protein abundance is translational
control.2
Translation initiation is rate limiting, highly regulated and
dependent on the coordinated action of eukaryotic initiation
factors (eIFs).3,4 TheDEAD-box helicase eIF4A1 is required to
unwind structured RNA elements within the 5′ untranslated
region (5′UTR) to facilitate ribosome binding and scanning, its
activity is stimulated by interaction with the proteins eIF4B5
and eIF4E,6 and inhibited by the tumor suppressor PDCD4.7
The isoform eIF4A2 can also participate in translation
initiation, but is also implicated in the function of
microRNAs.8 Structured 5′UTRs are inhibitory to translation
initiation,9 so alterations in helicase activity are expected to
have message-specific effects.
Alterations in the expression of several eIF4A1 activity-
modulating proteins have been observed in many cancers.
eIF4E is a well-established oncogene,10,11 and the translation
of several oncogenic mRNAs with long or structured 5′UTRs,
such as c-myc, cyclin D1 and ornithine decarboxylase (ODC)
were shown to correlate with eIF4E expression.12 eIF4B is
required for HeLa cell growth,13 and eIF4B overexpression
was associated with poor survival of lymphoma patients,
probably resulting from increased eIF4A1-dependent expres-
sion of DAXX, BCL2 and ERCC5.14 In contrast, high levels of
PDCD4 were associated with a reduction in the expression of
growth-promoting factors such as ODC and CDK4,15 and
correlate with good outcome in a small study of ER-positive
breast tumors,16 while levels were reduced in several tumor
types including breast adenocarcinoma.17
Expression of eIF4A1 itself has not been widely investigated
in tumors. However, the above findings and data from a
number of model systems implicate eIF4A1 in the malignant
phenotype. Inhibition of eIF4A results in reduced expression of
several oncogenes, including cyclin D1, Bcl-x and MUC1,18,19
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and improves chemosensitivity in mouse models of
lymphoma.19,20 In breast and prostate cancer xenograft
models, eIF4A inhibition enhanced apoptosis and diminished
tumor angiogenesis and proliferation.21 Recently, several
natural small molecules that inhibit eIF4A have been
described, notably silvestrol21 and hippuristanol,22 and there
is considerable interest in such agents as potential anti-cancer
treatments.
Given the evidence that eIF4A1-mediated helicase activity
may be a useful therapeutic target, we carried out a large-
scale study to investigate the prevalence and clinical
significance of the expression of eIF4A1 and its modulators
in breast cancer, and found all these proteins to have striking
relationships with survival. We went on to show that eIF4A1
activity is limiting for cell growth and cycling in cultured breast
cancer cells. Then, in order to find mechanisms linking
helicase activity to these phenotypes, we obtained the global
eIF4A1-dependent translatome in cultured MCF7 cells, and
demonstrated that numerous oncogenic mRNAs are directly
translationally upregulated by eIF4A1. These mRNAs are GC
rich, and enriched for motifs with the potential to form
G-quadruplexes.
Our data show that diverse modes of increased eIF4A1
helicase activity expand the translatome to allow growth
promotion, suggesting that eIF4A1 inhibitors could provide
good therapeutic options for patients with tumors exerting this
mechanism, and that simple immunohistochemical tests are
promising biomarkers to predict sensitivity.
Results
Expression of pro-helicase factors predicts poor out-
come in ER-negative disease. To assess eIF4A1 helicase
activity in breast tumors, tissue microarrays (TMAs) derived
from 3903 patients were scored for eIF4E, eIF4A1, eIF4B
and PDCD4 (summarized in Table 1 and Supplementary
Table 1). Representative images are shown in Figure 1.
When incorporated into univariate Cox survival models,
eIF4E, eIF4A1 and eIF4B all predict poor outcome in ER-
negative cases only (Figure 2 and Supplementary Table 2).
Only eIF4A1 showed a significant time-dependent compo-
nent. Multivariate models were constructed to further test
prognostic value. In ER-negative disease modeled with all
three pro-helicase factors, eIF4B maintained significance
(Table 2, model 1). When included in a model with all key
clinicopathological markers (HR=1.5, P=0.021; model 2).
When parsimonized by stepwise removal of non-significant
variables, the final model contained only eIF4B (HR=1.7,
P=0.002), HER2 and nodal status (model 3). eIF4A1 had
similar relationships when substituted into the same model
(model 4).
PDCD4 expression predicts good outcome in ER-
positive disease. The endogenous eIF4A1 inhibitor PDCD4
predicts good outcome in ER-positive disease when quanti-
fied in either the nucleus or the cytoplasm, although nuclear
PDCD4 performs better in a bivariate model with both
compartments (Table 2, model 5). In a model with all key
clinicopathological parameters including the proliferation
marker aurora kinase A, PDCD4 retained significance (HR=
0.7, Po0.001; model 6). In the parsimonized model, PDCD4
retained this hazard ratio alongside grade, nodal metastasis
and proliferation (models 7 and 8).
Association of translation initiation factors with PDCD4
and ER. eIF4E, eIF4A1 and eIF4B were associated
(Spearman’s ρ=0.31–0.34), possibly reflecting coregulation
(Supplementary Table 3). Nuclear and cytoplasmic PDCD4
were also associated (ρ= 0.41) reflecting the known nucleo-
cytoplasmic shuttling of this protein.23 PDCD4 correlates with
ER expression, especially nuclear PDCD4 (ρ=0.35).
Associations with clinicopathological variables. eIF4A1
and eIF4B were associated with higher histological
grade (Po0.001 and P=0.004) in ER-negative tumors
(Supplementary Table 4A and 4B). In ER-positive tumors,
PDCD4 was associated with lower grade, smaller size and
less nodal metastasis (P≤ 0.001).
eIF4A1, eIF4B and PDCD4 influence breast cancer cell
proliferation and cell cycle. We then sought causative
relationships among mediators of eIF4A1 helicase function,
cell growth and the cell cycle by screening a panel of breast
cancer cell lines (Figure 3a). MCF7 cells expressed high
levels of eIF4A1 and moderate levels of eIF4B and PDCD4,
and was chosen as a model cell line.
eIF4A1 and eIF4B were transiently decreased using siRNA,
and PDCD4 was overexpressed using a lentiviral vector
(Figures 3b and c). Growth curves were generated for control
and treated cells (Figure 3d), and the data show that
Table 1 Study population summary
Variable
Mean age (range in years) 53 (24–73)
Mean follow-up (range in years) 9.9 (0.6–20.2)
Number of breast cancer deaths (%) 582 (15)
5-Year survival (%) 3316 (85)
Category Number (%)
Age at diagnosis ≤55 2330 (60)
455 1573 (40)
Missing 0
Grade 1 753 (19)
2 1625 (42)
3 1077 (28)
Missing 448 (11)
Nodes 0 2182 (56)
1–3 979 (25)
43 370 (9)
Missing 372 (10)
Size o20mm 2083 (53)
20–49mm 1465 (38)
≥50mm 132 (3)
Missing 223 (6)
ER Negative 772 (20)
Positive 2287 (59)
Missing 844 (22)
HER2 Negative 2558 (66)
Positive 349 (9)
Missing 996 (26)
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decreased helicase activity significantly slowed down cellular
proliferation.
The proportion of cells in S phase of the cell cycle was
determined (Figure 3e) and in all cases decreased helicase
activity was associated with a reduction of the S-phase
fraction, indicating that eIF4A1 activity favours entry into
S phase.
A subset of mRNAs is dependent on eIF4A1 for efficient
translation. We then sought to define the eIF4A1-
dependent translatome. Sucrose-gradient ultracentrifugation
was used to isolate total, polysomal and subpolysomal
mRNA fractions from control cells or cells where eIF4A1
levels were reduced by siRNA. The decreased eIF4A1
expression resulted in a small increase in free ribosomal
subunits, consistent with slight global reduction in protein
synthesis (Figure 4a).
RNAseq libraries were generated and sequenced by
Illumina HiSeq (Illumina, San Diego, CA, USA), and transcript
and gene expression levels were estimated using MMSEQ.24
To validate the quantification method, we compared levels
from RNA sequencing with estimates obtained using
microarray analysis of the same biological starting material.
Overall, results from the two methods correlated strongly
(Supplementary Figure 1; median Spearman’s ρ=0.70),
especially for highly expressed genes. Reduced correlation
for genes with low expression is consistent with a reduced
dynamic range for microarrays due to non-specific hybridiza-
tion. Our subsequent analyses utilized the RNAseq data only.
To identify helicase-dependent (i.e., more polysomal/trans-
lated in the presence of eIF4A1) and -independent (i.e., the
inverse tendency) mRNAs, a recently described Bayesian
model selection method, MMDIFF,25 was employed on the
RNAseq data (Figure 4b and Supplementary Table 5). One
hundred seventy-five eIF4A1-dependent mRNAs that shift
Figure 1 Representative immunohistochemistry images. Photomicrographs of representative TMA cores were taken. (a) eIF4E (strong cytoplasmic staining), (b) eIF4A1
(strong cytoplasmic staining), (c) eIF4B (moderate cytoplasmic staining) and (d) PDCD4 (strong nuclear staining and moderate cytoplasmic staining). Scale bar= 100 μm
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from polysomes to subpolysomes following eIF4A1 knock-
down were identified, as were 49 mRNAs which show
paradoxical translational upregulation following knockdown.
To validate these effects, we examined protein levels of
several genes identified as eIF4A1 dependent or independent
by immunoblotting (Figure 4c). We also tested the effect of
eIF4A1 knockdown on the oncogene PI3KCA; although not
identified in our screen PI3KCA that harbors a known driving
mutation in MCF7 cells.26 PI3KCAwas also seen to be eIF4A1
dependent at the protein level.
eIF4A1 dependence is related to 5′UTR structure. Since
eIF4A1 is believed to unwind structures in 5′UTR mRNA, we
sought properties of 5′UTRs associated with eIF4A1 depen-
dence (Figure 5 and Supplementary Table 6). G/C content
proved to be the most significant determining factor
(Figure 5a; P=6.2e–12). The predicted minimum free-
folding energy of the whole 5′UTR (ΔG) showed a significant
but weaker relationship (P=3.6e–3; Figure 5b). There was
no significant relationship with 5′UTR length (Figure 5c) or
the presence of upstream AUG start codons.
We went on to seek enriched motifs up to 12-nt long
using the MEME motif elicitation software27 within the
eIF4A1-dependent messages, as compared to scrambled
sequence. The most significantly identified motifs were a
U-rich tract (e-value=1.4e–43; Figure 5d), a G/A-rich motif
including the consensus GGAGG (e=3.3e–30), and a G/C-
rich motif of the form GC(GGC)3G (e= 1.9e–34).
When we examined the eIF4A1-dependent and eIF4A1-
independent groups for the numbers of UTRs that contain the
identified motifs, we found that the (GGC)-repeat motif was
enriched in the eIF4A1-dependent group (62 versus 35%,
P= 0.0015; Figure 5e). The G/A-rich motif was even more
enriched in this group (22 versus 13%) but did not meet
nominal significance (P=0.15). The U-rich motif in contrast
showed the opposite trend (5 versus 10%, P= 0.31).
The (GGC)n repeat motif is highly suggestive of G-quad-
ruplex formation, and (GGC)4 RNA repeats have recently
been shown to have G-quadruplex–forming properties.28 The
GGAGG motif also has higher-order folding potential; two
GGAGG motifs connected by a short linker can fold to form a
compact structure containing a G-quadruplex, and two of
these can form a dimeric RNA G-quadruplex structure
in trans.29
We therefore interrogated the sequences of the eIF4A-
dependent and eIF4A-independent 5′UTRs for the potential to
Figure 2 Kaplan-Meier graphs. Curves show survival of patient cohorts defined by their expression of factors that influence mRNA helicase activity as measured by
immunohistochemistry. eIF4E, eIF4A1 and eIF4B stains are quantified in the cytoplasm, and PDCD4 in the nucleus. Numbers at risk are listed in Supplementary Table 9. P-values
refer to the log-rank test for trend across expression categories, calculated over 10 years in all cases except for eIF4A1; this variable shows time dependence and the test is
calculated over the first 3 years only
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form these structures. The eIF4A-dependent group is rela-
tively enriched for G-quadruplex–forming sequences (80
versus 36%, P= 0.0014) as well as paired GGAGG motifs
(12 versus 4%, P= 0.17; Figure 5e).
eIF4A1 dependence identifies genes with diverse roles in
the malignant phenotype. We examined the eIF4A1-
dependent and -independent subsets of mRNAs (Figure 4b)
for statistically over-represented structural protein families
using GeneTrail30 (Supplementary Table 7). The group of 175
eIF4A1-dependent transcripts is enriched for three structural
protein families: G-protein α-subunits (P= 3.9e–6), cyclin
N-terminal domains (P=3.1e–3) and serine-threonine protein
kinases (P=3.2e-3). We noticed that this group also
contained several other genes involved in oncogenic signal-
ing pathways, such as TGFB1, SMAD2, ARAF and the CDK1
cyclin activator CDC25B.
We then analyzed a list of all genes ranked by eIF4A1
dependence by gene set enrichment analysis (GSEA)31
(Supplementary Table 7). This identified numerous signaling
pathways, including IP3/calcium, FGFR, EGFR and HER2
pathways (FDR q-value near to 0), as well as MAP kinase
(q= 0.022) and TGF-beta pathways (q=0.071). This was
accompanied by association with gene-ontological (GO)
categories such as amino acid phosphorylation (q=0.055)
and chromatin modification (FDR= 0.092). In addition, several
malignant KEGG categories were enriched including color-
ectal (q= 1.1e–3), endometrial (q=2.1e–3) and renal cell
carcinomas (q=0.032).
eIF4A1-independent genes are related to DNA repair and
apoptosis. The list of 49 eIF4A1-independent genes shows
over-representation of zinc finger proteins (P=0.010). In
GSEA analysis, the eIF4A1-independent arm was enriched
for the ATM DNA damage pathway (q= 0.015), alongside
annotations for DNA damage resulting in apoptosis (q=0.11)
and ribosomal proteins (q=0.078).
eIF4A1 dependence is related to the presence of miRNA
target sites. We then tested for enrichment of mRNAs with
predicted 3′UTR miRNA target sites. This large list of genes
accounting for almost half the annotated mRNAs was highly
enriched for eIF4A1 dependence (q=6.9e–3).
Discussion
Markers of helicase activity as prognostic and predictive
biomarkers in breast cancer. We showed that the expres-
sion of proteins that drive or inhibit the unwinding of 5′UTRs
was strongly predictive of outcome in breast cancer, in ways
that were independent of known influential variables. This
suggested that dysregulation of translational control affected
tumor biology in other, unmodeled ways.
Expression of eIF4A1 and its stimulatory partners eIF4E
and eIF4B all predicted poor outcome in ER-negative disease
only. eIF4A1 and eIF4B predicted poor outcome in ER-
negative tumors independently of lymph node status, which is
the most influential single predictor of outcome in this group.
Table 2 Multivariate Cox regression survival models
Model (person-years
of follow-up)
Variable n (deaths) HR (95% CI) P T HR (95% CI) T P
ER-Negative 1 (1571) eIF4E 259 (63) 1.2 (0.9–1.5) 0.291
eIF4A1 1.9 (0.9–4.0) 0.083 0.6 (0.3–0.9) 0.024
eIF4B 1.6 (1.0–2.4) 0.037
Grade 292 (70) 1.1 (0.7–1.7) 0.554
2 (1796) Nodes 2.1 (1.5–2.9) o.001
Size 1.1 (0.7–1.6) 0.759
HER2 1.8 (1.0–2.9) 0.03
eIF4B 1.5 (1.1–2.1) 0.021
3 (2083) Nodes 338 (74) 2.2 (1.6–2.9) o0.001
HER2 1.7 (1.0–2.8) 0.039
eIF4B 1.7 (1.2–2.4) 0.002
4 (2853) Nodes 466 (108) 2.4 (1.9–3.1) o0.001
HER2 1.2 (1.0–2.4) 0.03
eIF4A1 2.1 (1.2–3.6) 0.006 0.6 (04–0.9) 0.017
ER-Positive 5 (10 686) PDCD4(nuc) 1584 (171) 0.6 (0.5–0.7) o0.001
PDCD4(cyt) 0.8 (0.6–1.0) 0.104
6 (6789) Grade 967 (110) 1.5 (1.1–2.1) 0.008
Nodes 2.3 (1.8–3.0) o0.001
Size 1.3 (0.9–1.8) 0.143
HER2 1.6 (0.9–2.6) 0.08
Aurora kinase 1.3 (1.1–1.6) 0.008
PDCD4(nuc) 0.7 (0.6–0.8) o.001
7 (7402) Grade 1044 (117) 1.6 (1.2–2.1) 0.004
Nodes 2.5 (1.9–3.1) o0.001
Aurora kinase 1.3 (1.1–1.6) 0.005
PDCD4(nuc) 0.7 (0.5–0.8) o0.001
8 (7402) Grade 1044 (117) 1.8 (1.3–2.4) o0.001
Nodes 2.5 (1.9–3.1) o0.001
Aurora kinase 1.3 (1.1–1.6) 0.009
PDCD4(cyt) 0.7 (0.5–0.9) 0.003
T HR and T P refer to the time-varying components of models incorporating eIF4A1
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This is unusual and potentially clinically useful. First, there are
very few independent prognostic factors apart from lymph
node status reported in these aggressive and pharmacologi-
cally intractable tumors, rare exceptions being a transcrip-
tional signature related to immunity32 and the stem cell marker
integrin alpha-6.33 Second, it indicates that helicase activity
affects more than just proliferation, as proliferation is known to
have little if any relationship with survival in ER-negative
cases.34 Third, these proteins hold promise as biomarkers to
direct anti-helicase therapy.
In ER-positive disease, both nuclear and cytoplasmic
PDCD4 expression predicted good outcome, with moderate
and high-expressing cases being at less than one-third the
hazard of tumors without detectable protein, even after taking
known predictive variables into consideration. This further
suggests that any survival benefit of PDCD4 expression and
consequent helicase inhibition is not solely due to effects on
cellular proliferation.
There is a great need for biomarkers to identify patients with
ER-positive tumors who are at low risk of recurrence and who
Figure 3 mRNA helicase activity reduction decreases MCF7 cell proliferation by interfering with the progression through cell cycle. (a) Immunoblot analysis of endogenous
eIF4A1, eIF4B and PDCD4 protein expression in nine breast cancer cell lines. (b) Immunoblot analysis of eIF4A1 and eIF4B expression showing the efficacy of siRNA
knockdown. (c) Immunoblot analysis of PDCD4 expression showing the overexpression of PDCD4 in stably transfected MCF7 cells. (d) Growth curves for cultured MCF7 cells
treated with anti-eIF4A1 or anti-eIF4B siRNA or control siRNA, or cells stably overexpressing PDCD4 and control cells. Growth curves were obtained by confluency
measurements using IncuCyte (for eIF4A1 knockdown and PDCD4 overexpression) or counting cells using ViCell (for eIF4B knockdown). Points, mean value of at least a triplicate
for a typical experiment; significance indicated by *Po0.05 and ***Po0.001, as determined by two-way ANOVA. (e) Flow cytometric analysis of BrdU and PI incorporation to
determine percentage of cells in S phase on eIF4A1 or eIF4B knockdown or PDCD4 overexpression. Data are representative of two biological replicates including at least one
technical duplicate. Significance indicated by *Po0.05 and **Po0.01, as determined by t-test
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might be spared unnecessary chemotherapy, and PDCD4
expression shows potential in this role. Low PDCD4 levels
might also identify candidates for anti-helicase therapy.
Subcellular location of PDCD4 was of little relevance to its
value as a prognostic factor (Table 2). However, nuclear
PDCD4 displaced cytoplasmic PDCD4 from a bivariate
survival model and it had somewhat different clinicopatholo-
gical correlations. The significance of this is not clear,
particularly as PDCD4 is known to shuttle, but might be
related to putative additional nuclear functions of the protein.35
Helicase activity and cell growth. All manipulations
of eIFs and PDCD4 intended to decrease helicase
activity caused diminished proliferation and entry of
cells in S phase, consistent with previous findings
regarding the individual inhibition of eIF4A1 and eIF4B in
leukemia19 and HeLa cells.13 In addition, our finding that
we could replicate the inhibitory effect on cell growth by
overexpressing PDCD4 was consistent with the known
inhibitory effect of PDCD4 on eIF4A1 function, and
supports a role for PDCD4 expression in restricting tumor
growth.
This suggests that multiple convergent mechanisms might
be exploited by cancer cells to influence helicase activity
thereby achieving similar dysregulatory and phenotypic
effects.
Figure 4 A subset of mRNAs is dependent on eIF4A1 for efficient translation. MCF7 cells were transfected with either control siRNA or anti-eIF4A1 siRNA and analyzed
48 h post-transfection. (a) Polysome analysis of RNA. Ribosomes were stalled with cycloheximide and mRNAs separated according to their ribosome load by sucrose-
gradient centrifugation. The positions of the 40S, 60S and 80S ribosomal subunits and polysomal peaks are indicated, as well as fractions pooled for subsequent mRNA
analysis. (b) Identification of eIF4A1-dependent and -independent messages. mRNAs from pools indicated in control and eIF4A1 knockdown MCF7 cells were quantified by
RNA sequencing (the experiment was performed in quadruplicate). The Bayesian model was applied to identify mRNAs that show significant shifts between polysomes and
subpolysomes following eIF4A1 knockdown. Each mRNA identified was plotted according to log-fold change in the subpolysomal and polysomal fractions; mRNAs below
y= x are translationally downregulated (eIF4A1-dependent mRNAs) and mRNAs above y= x show the reverse tendency (eIF4A1 independent). Colored lines drawn through
each mRNA plot point show the change in the separately quantified total mRNA abundance. This confirms that in general the modeled changes in fractionated mRNAs are
reflected at the total mRNA level, that is, an mRNA seen to go up in both subpolysomal and polysomal fractions generally shows an increased total abundance.
(c) Immunoblot analysis of protein levels of eIF4A1-dependent and -independent messages. Translationally upregulated proteins increase at the protein level and vice versa.
The experiment was performed in triplicate. Significance indicated by *o0.05 and ***o0.01
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The eIF4A1-dependent translatome. A cohort of mRNAs
was seen to be reliant on eIF4A1 expression for their effective
translation, and a smaller group showed surprising recruit-
ment into polysomes when eIF4A1 levels were decreased.
These shifts were validated at the mRNA level by parallel
microarray data, and at the protein level by immunoblotting.
The 175 helicase-dependent mRNAs encode a range of
proteins implicated in oncogenesis, many of which are
involved in intracellular signaling pathways. Therefore
upregulation of helicase activity would be expected to be
advantageous to a malignant clone. Conversely, inhibition of
eIF4A1 would be expected to result in ‘dampening’ of the
same pathways with widespread normalizing effects upon the
malignant phenotype.
In contrast, the group of 49 eIF4A1-independent mRNAs is
enriched for pathways related to DNA damage detection and
induction of apoptosis, and are less structured and G/C rich.
They present a paradox; how can reduced mRNA helicase
Figure 5 eIF4A1-dependent and -independent mRNAs have qualitatively different 5′UTRs. eIF4A1-dependent and -independent mRNA 5′UTRs were characterized in terms
of (a) G/C content, (b) predicted folding stability and (c) 5′UTR length. P-values were calculated using Kolmogorov-Smirnov test. (d) Recurrent sequence motifs were discovered
in the eIF4A-dependent 5′UTRs. (e) GGC-containing motifs were enriched in eIF4A-dependent sequences, as was the predicted potential to form classical G-quadruplexes
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activity result in their translational upregulation? This is likely
to be the result of enhanced availability of other components of
the initiation machinery due to the reduced translation of
eIF4A-dependent mRNAs. The observed enrichment for
ribosomal protein mRNAs is consistent with this model, as
they generally have short 5′UTRs containing terminal oligo-
pyrimidine tracts (TOPs) with little potential for structure
formation.
These findings enable us to construct a model for how
dysregulation of translation initiation contributes to the
malignant phenotype in breast cancer. Upregulation of pro-
helicase activity proteins (eIF4A1, eIF4E and eIF4B) or
downregulation of PDCD4 all lead to enhanced mRNA
unwinding, which results in the specific translational upregula-
tion of numerous proteins involved in cell signaling and
proliferation. The result is enhanced signaling throughmultiple
major mitogenic and oncogenic signaling pathways, favouring
growth, entry into S phase and other aspects of the malignant
phenotype in many ways. The detailed description of these
mechanisms will require further work.
Unwinding of G-quadruplexes due to enhanced eIF4A
activity implicated in the phenotype of solid malignancy.
We found that eIF4A1-dependent mRNAs have 5′UTRs with
higher G/C content and greater predicted stability of
secondary structure. Furthermore, they were enriched for
sequence motifs containing (GGC)n motifs, and for predicted
G-quadruplex–forming sequences. In addition, a GGAGG
-containing element suggests further capacity for novel
structure formation; these elements can form stable stacked
structures of GGAGGA hexads and GGGG tetrads, and can
do so in trans.29
These findings are complementary to a recent study of
changes in translation brought about by eIF4A inhibition in a
cultured T-cell acute lymphoblastic leukemia cell line.28 In that
study, use of a non-specific eIF4A inhibitor in a cell line
expressing high levels of eIF4A2 also led to translational
downregulation of mRNAs enriched for G-quadruplex–forming
sequences. The different roles of eIF4A1 and eIF4A2 are the
subject of current debate, but taken together with our study this
suggests that in some circumstances eIF4A1 and eIF4A2may
both be involved in the malignant phenotype via their capacity
to unwindG-quadruplex structures. Our findings also, critically,
extend this mechanism to epithelial malignancy and show
relationships between eIF4A expression, the expression of
endogenous eIF4A cofactors and inhibitors, and phenotypes
at the cellular and patient survival levels.
Translation initiation as a nexus for dysregulation of
gene expression in several cancers. A recent study
showed that maintenance of eIF4F, the complex containing
eIF4A activated by eIF4E via its interaction with eIF4G6 was
the common route for the acquisition of resistance to
therapeutic drugs targeting mutant BRAF in melanoma cell
lines and patients.36 Furthermore, eIF4A inhibitors showed
synergistic effects on cellular proliferation in combination with
anti-BRAF therapy.
Another study recently showed that predicted 5′UTR
structure correlated with the presence of miRNA-binding sites
in the 3′UTR, and was necessary to enable miRNA function8
with the implication that helicase dependence may be central
to the miRNA mechanism. These data are consistent with our
finding that eIF4A1-dependent mRNAs are highly enriched for
miRNA target sequences. These same genes would be
expected to be dysregulated by 3′UTR shortening and global
miRNA loss, both of which are reported in a number of
malignancies. We suggest that all three of these mechanisms
(miRNA loss, 3′UTR shortening and helicase upregulation)
contribute to malignant behavior by the derepression of the
same group of eIF4A1-dependent mRNAs. Further character-
ization of these genes and the similarities between these
modes of dysregulation will add significantly to our under-
standing of the malignant phenotype.
Taken with our findings that measures of eIF4A activity in
breast tumor tissue are predictive of outcome, these studies
provide further evidence that enhanced helicase activity is a
key determinant of themalignant phenotype in a diverse range
of malignancies. The eIF4G complex in general, and eIF4A
mRNA helicase activity in particular, represent one of the most
promising new therapeutic targets in many human cancers,
and the way is clear for further studies and clinical trials.
Materials and Methods
Study populations and tissue arrays. The Study of Epidemiology and
Risk Factors in Cancer Heredity (SEARCH) was used as the basis for
immunohistochemical studies.37 In total, 3903 patients were included (summarized
in Table 1). TMAs derived from this population have been used in several previous
studies.33,34,38
Immunohistochemistry. Immunostaining was performed using a Bond
polymer refine kit and a Leica Bond-max autostainer (Supplementary Table 8).
Immunohistochemical data for ER and aurora kinase A expression have been
previously described in detail.34,38,39 Negative controls were performed simulta-
neously. Assay specificity was checked using cytoblocks prepared from cultured
cells with siRNA knockdown (Supplementary Figure 2). Nine from a total of 118
arrays stained were deemed technical failures and excluded.
Imaging and scoring. Core images were collected using an Ariol image
capture system (Applied Imaging Corp, San Jose, CA, USA), and examined
without knowledge of clinicopathological data. All markers displayed only
minor variability between tumor cells, so staining intensity alone was recorded.
Scores were given for the predominant intensity of staining, on a scale of 0–3
(0= negative, 1=weak, 2=moderate and 3= strong). eIF4B was scored on a
scale of 0–2 due to relatively reduced dynamic range.
In total, 59% of cores provided data (8156 of 13 803). Missing data were due to
cores ‘cutting out’, as many of the arrays have been extensively used, poor core
adherence or inadequate tumor cellularity.
Statistical methods. Lymph node status was divided into 0, 1–3 and 4, or
more positive regional lymph nodes. Tumor stage was divided into TNM stage 0,
stages 1–2 and stages 3–4. Tumor size was divided intoo2, 2–4.9 and44.9 cm.
When ordinal immunohistochemical variables were binarized, the cutoff was set at
the first category above 0 that showed nominally significant prognostic value in a
univariate Cox model. Associations between ordinal variables were quantified by
Spearman's rank correlation with Pearson’s chi-squared test. Other associations
were tested using Fisher’s exact test or Pearson’s chi-squared test. The study
complies with the REMARK (reporting recommendations for tumor-marker
prognostic studies) criteria.40 STATA/SE13 (Statacorp, College Station, TX, USA)
was used for statistical analyses.
Cox regression survival modeling. The proportional-hazards assumption
was verified by inspection of log-log plots. eIF4A1, eIF4B, eIF4E and PDCD4 were
modeled as ordinal values, as all four variables showed incremental unidirectional
changes in hazard ratio in univariate survival models had positive log-rank trend
tests across categories (Figure 2). The measured outcome was breast cancer-
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related death, and survival analysis was restricted to 10 years after entry into the
SEARCH study. Compensation was made for left truncation of data.41 Numbers at
risk in Kaplan-Meier analyses are listed in Supplementary Table 9.
Cell lines and cell culture. All cell lines used were authenticated in
2011–2012 using Promega GenePrint10 STR profiling kit (Promega Corporation,
Madison, WI, USA). The cell lines T47D, MCF7, CAMA1, SKBR7 and MDA-MB-231
were grown in DMEM, HCC1954 and PMC42 were grown in RPMI, Hs578T was
grown in DMEM supplemented with 10 μg/ml insulin, and VP229 were grown in
DMEM F12. All media were supplemented with 10% FBS (Life Technologies,
Carlsbad, CA, USA).
Knockdown and overexpression. Control ON-TARGETplus Non-targeting
Pool and ON-TARGETplus SMARTpool siRNAs targeting eIF4E, eIF4A1 or eIF4B
were transfected into cells according to manufacturer’s instructions (Thermo
Scientific, Waltham, MA, USA) using DharmaFECT 1 transfection reagent (Thermo
Scientific; eIF4A1) or Lipofectamine RNAi MAX (Life Technologies; eIF4E and
eIF4B).
High-titer viral particles including Precision LentiORF RFP control and Precision
LentiORF PDCD4 clone were purchased from GE Healthcare (Little Chalfont,
Buckinghamshire, UK) and used according to manufacturer’s instructions to generate
a cell line stably overexpressing PDCD4.
Immunoblotting. Blots were probed using the following primary antibodies:
anti-eIF4E (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-9976), anti-eIF4A1
(Abcam, Cambridge, UK; ab31217), anti-eIF4B (Epitomics, Burlingame, CA, USA;
2232-1), anti-PDCD4 (Abcam, ab80590), anti-actin (Abcam, ab6276), CCND3 (Cell
Signaling, Beverly, MA, USA; 2936), PI3KCA (Cell Signaling, 4249), CDC25B (Cell
Signaling, 9525), NPM1 (Cell Signaling, 3542), GNAS (Abcam, ab83735), RPL27A
(Abcam, ab74731), hnRNPA1 (Abcam, ab4791) and RPS25 (GeneTex, Irvine, CA,
USA; 101526). Suitable secondary antibodies were used for chemiluminescence
detection. Samples were analyzed from at least two independent experiments.
Films were scanned on an ImageScanner III using LabScan software
(GE Healthcare) and proteins were quantified using ImageQuant software
(GE Healthcare), or for Licor analysis, IRDye 680LT-conjugated secondary antibody
(LI-COR Biosciences, Lincoln, NE, USA) was used, followed by scanning on the
Odyssey system (LI-COR Biosciences).
Cell proliferation assays. Cell number was determined either by direct
counting using a ViCell XR cell viability analyzer (Beckman Coulter, Miami, FL,
USA) using trypan blue cell viability assay or by monolayer confluence readings as
calculated from images acquired by Essen IncuCyte (Essen BioScience, Ann Arbor,
MI, USA). All data are a mean of at least three replicates.
Cell cycle analysis. The fraction of proliferating cells in S phase was
determined by bromodeoxyuridine (BrdU) incorporation. Cells were incubated with
10 μM BrdU (Sigma-Aldrich, St. Louis, MO, USA) in normal culture medium for 1 h,
fixed, washed, resuspended in denaturing solution for 20 min at room temperature,
washed and resuspended in 0.5-ml neutralizing solution for 2 min, and washed
again. BrdU incorporation was determined using a BrdU flow kit (BD Pharmingen,
Franklin Lakes, NJ, USA). Washed cells were stained with propidium iodide and
incubated for 1 h in darkness. Flow cytometric analysis was performed on a BD
FACSCalibur flow cytometer with the CellQuest Pro software (BD Biosciences,
Franklin Lakes, NJ, USA). The data were analyzed using FlowJo software (TreeStar,
Inc., Ashland, OR, USA).
Sucrose density gradient polysome profiling. Cytoplasmic lysates
were fractionated to produce polysomal and subpolysomal populations of mRNAs
as described previously.14 Pooled mRNAs were purified using a miRNeasy kit
(Qiagen, Valencia, CA, USA).
Gene expression microarrays. Total, subpolysomal and polysomal RNA
was analyzed using Illumina gene expression microarrays (Human H12 v4
Beadchips; Illumina) according to the manufacturer’s instructions. Data were
processed using a number of Bioconductor packages.42 The beadarray
package43,44 was used for adjustment for spatial artifacts and quality assessment,
and LOWESS normalization was applied to log2 transformed data. A probe-wise
linear model was fitted to the data using Limma45 and the empirical Bayes method
was used to identify statistically significant differentially expressed genes. The
Benjamini-Hochberg method was used to control the false discovery rate.46
Hierarchical clustering of samples was based on Euclidean distance and complete
linkage using the hclust function in R.
RNA sequencing analysis. RNA sequencing libraries were created using
Illumina TruSeq RNA sample preparation kit v2 (Illumina), and paired-end
sequenced on a HiSeq 2000 to a length of 100 bp, using SBS chemistry version
3 from Illumina.
The RNAseq reads were aligned to version 68 of the Ensembl human reference
cDNA and ncRNA sequences using Bowtie 147 allowing for multi-mapping between
reads and transcripts. The MMSEQ gene expression analysis software24 was used
to estimate transcript expression levels. To perform a like-for-like comparison to
microarray estimates, the MMSEQ marginal posteriors for the set of Ensembl 68
transcripts mapped to by each Illumina BeadChip probe were collapsed. Similarly,
MMSEQ collapses marginal posteriors for the set of transcripts belonging each gene,
thus providing gene-level expression estimates. The marginal posterior mean and S.
D. of the log expression parameter corresponding to each transcript or set of
transcripts (i.e., gene or probe) was then used as the outcome in a Bayesian model
selection algorithm implemented in the MMDIFF software.25 The competing models
are regression based and thus they can accommodate complex experimental
designs. For differential expression analysis, we compared models using the following
design matrices:
Mð0Þ ¼ 11111111ð ÞT
Mð1Þ ¼ 1 1 1 1 1 1 1 1
0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5
 T
Where the first four rows correspond to one condition (e.g., knockdown samples in
total unfractionated mRNA) and the last four rows correspond to another condition
(e.g., control samples in the total unfractionated mRNA). The matrices were
transposed to optimize the use of space.
In order to assess whether the log-fold change in expression between control
and knockdown samples differed between subpolysomes and polysomes
(i.e., a difference-of-difference analysis), models were compared using the following
design matrices:
Mð0Þ ¼
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5
0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5
0
@
1
A
T
Mð1Þ ¼
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5
0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0:5 0:5 0:5 0:5 0:5 0:5 0:5 0:5
0
BB@
1
CCA
T
Where the rows correspond to subpolysomal RNA (eIF4A1 siRNA), subpolysomal
RNA (control siRNA), polysomal RNA (eIF4A1 siRNA) and polysomal RNA (control
siRNA), respectively in consecutive sets of four replicates.
In both sets of model comparisons, the prior distributions for the intercepts and
other coefficients were set as described previously,25 while the probability of the more
complex model being true was set to 10%. The posterior probability of the more
complex model or, equivalently, a Bayes factor, was used as the basis for preferring
the more complex model (differential expression or difference of difference,
respectively) to the simpler model.
As the competing models are regression based, they may include, for instance,
both an eIF4A1 siRNA versus ctrl siRNA effect and a polysomal versus subpolysomal
effect on expression. To identify helicase-dependent mRNA transcripts, the simple
model assumed that the log-fold change between subpolysomal (eIF4A1 siRNA) and
subpolysomal (control siRNA) was the same as between polysomal (eIF4A1 siRNA)
and polysomal (control siRNA), while the more complex model allowed the log-fold
changes to differ. A prior probability of 0.1 that the complex model was true was
specified and initially thresholded liberally on a posterior probability of 0.2 that the
complex model was true in order to declare a transcript helicase dependent.
Our confidence in using this liberal threshold was increased by the strong
correlation seen between modeled shifts between changes in polysomal and
subpolysomal mRNA levels and total mRNA levels (Figure 4b), by reflection of
predicted changes in translation at the protein level (Figure 4c), and by the strong
relationship seen between helicase dependence and 5′UTR G/C content (Figure 5a).
5′UTR sequence analysis. The 5′UTR sequences of 84888 protein-coding
transcripts were obtained from Ensembl Genome Browser (version 68) using the
Ensembl Perl API.48 Minimum free energies (ΔG) of 5′UTR secondary structures
were calculated using the Vienna RNA package (version 1.8.5).49 Kolmogorov-
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Smirnov test was performed to investigate whether there were significant
differences between eIF4A1-dependent and -independent groups.
Sequence motifs within the eIF4A-dependent group of transcripts were discovered
using the MEME suite of tools.27,50 Where more than one transcript from one gene
was present, only the longest UTR sequence was used; 156 sequences were used in
the analysis. Motifs up to 12-nt long were sought in the 5′UTR sequences against the
same sequences randomized using DREME. Frequencies of discovered motifs in
eIF4A1-dependent and -independent mRNAs were assessed using the FLAG
algorithm. G-quadruplex–forming potential was defined as the presence within the 5′
UTR sequence of GG*GG*GG*GG or GGG*GGG*GGG*GGG where * is 1–7 of any
nucleotide sequence. GGAGG-motif–forming potential was defined as the presence
of GGAGG*GGAGG where * is 4–10 of any nucleotide.
Gene annotation analyses. Over-representation analyses of eIF4A1-
dependent and -independent groups were performed using GeneTrail.30 GSEA
was performed using the Broad Institute package.31,51 For GSEA, the list of
transcripts was ranked by eIF4A1 dependence calculated as posterior probability x
sign of shift between polysomal and subpolysomal fractions (Supplementary Figure
3). The list was rendered non-redundant by selection of the isoform with the highest
posterior probability. Predicted miRNA targets were downloaded from TargetScan-
Human (release 6.2).52
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